BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arachchillage DRJ, Mackie IJ, Efthymiou M, Chitolie A, Hunt BJ, Isenberg DA, Khamashta M, Machin SJ, Cohen H. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Thromb Haemost 2016;14:2177-86. [DOI: 10.1111/jth.13475] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, Salmon JE, Shoenfeld Y, Shovman O, Hunt BJ. Antiphospholipid syndrome. Nat Rev Dis Primers 2018;4:17103. [PMID: 29321641 DOI: 10.1038/nrdp.2017.103] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 21.5] [Reference Citation Analysis]
2 Willis R, Cohen H, Giles I, Knight JS, Krilis SA, Rahman A, de Groot PG. Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndrome. Cham: Springer International Publishing; 2017. pp. 77-116. [DOI: 10.1007/978-3-319-55442-6_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
3 Nguyen VA, Riddell N, Crewther SG, Faou P, Rajapaksha H, Howells DW, Hankey GJ, Wijeratne T, Ma H, Davis S, Donnan GA, Carey LM. Longitudinal Stroke Recovery Associated With Dysregulation of Complement System-A Proteomics Pathway Analysis. Front Neurol 2020;11:692. [PMID: 32849183 DOI: 10.3389/fneur.2020.00692] [Reference Citation Analysis]
4 Rand JH, Wu XX, Wolgast LR, Lei V, Conway EM. A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. Thromb Res 2017;156:119-25. [PMID: 28628799 DOI: 10.1016/j.thromres.2017.06.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 Dörner T, Lipsky PE. Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol 2016;12:645-57. [PMID: 27733759 DOI: 10.1038/nrrheum.2016.158] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
6 Sciascia S, Radin M. Thrombotic antiphospholipid syndrome. Lupus 2018;27:21-7. [PMID: 30452325 DOI: 10.1177/0961203318801686] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan X, Salta S, Gerotziafas G, Jing Z, Elalamy I, Wahl D, Zuily S. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmunity Reviews 2018;17:1011-21. [DOI: 10.1016/j.autrev.2018.04.009] [Cited by in Crossref: 72] [Cited by in F6Publishing: 52] [Article Influence: 18.0] [Reference Citation Analysis]
8 Dufrost V, Risse J, Zuily S, Wahl D. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep 2016;18. [DOI: 10.1007/s11926-016-0623-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
9 Radic M, Pattanaik D. Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome. Front Immunol 2018;9:969. [PMID: 29867951 DOI: 10.3389/fimmu.2018.00969] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
10 Khodashahi M, Rezaieyazdi Z, Sahebari M. Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review. Arch Rheumatol 2020;35:107-16. [PMID: 32637926 DOI: 10.5606/ArchRheumatol.2020.7375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 van den Hoogen LL, van Laar JM. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. Best Pract Res Clin Rheumatol 2020;34:101485. [PMID: 32067925 DOI: 10.1016/j.berh.2020.101485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Giles I, Cohen H, Ioannou Y. Pathogenesis of Antiphospholipid Antibody Syndrome. Dubois' Lupus Erythematosus and Related Syndromes. Elsevier; 2019. pp. 324-37. [DOI: 10.1016/b978-0-323-47927-1.00024-4] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Dufour I, Venot Q, Aydin S, Demoulin N, Canaud G, Morelle J. mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report. American Journal of Kidney Diseases 2020;76:288-91. [DOI: 10.1053/j.ajkd.2019.08.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Ramirez GA, Efthymiou M, Isenberg DA, Cohen H. Under crossfire: thromboembolic risk in systemic lupus erythematosus. Rheumatology 2019;58:940-52. [DOI: 10.1093/rheumatology/key307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
15 Andrade D, Cervera R, Cohen H, Crowther M, Cuadrado MJ, Canaud G, Garcia DA, Gerosa M, Ortel TL, Pengo V, Rahman A, Salmon JE, Willis R, Woller SC, Erkan D, Lockshin MD, Tektonidou MG. 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndrome. Cham: Springer International Publishing; 2017. pp. 317-38. [DOI: 10.1007/978-3-319-55442-6_18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Weiss L, Keaney J, Szklanna PB, Prendiville T, Uhrig W, Wynne K, Kelliher S, Ewins K, Comer SP, Egan K, O'Rourke E, Moran E, Petrov G, Patel A, Lennon Á, Blanco A, Kevane B, Murphy S, Ní Áinle F, Maguire PB. Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. J Thromb Haemost 2021. [PMID: 34161660 DOI: 10.1111/jth.15434] [Reference Citation Analysis]
17 Bala MM, Paszek E, Lesniak W, Wloch-Kopec D, Jasinska K, Undas A. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev 2018;7:CD012534. [PMID: 30004572 DOI: 10.1002/14651858.CD012534.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
18 Vreede AP, Bockenstedt PL, Knight JS. Antiphospholipid syndrome: an update for clinicians and scientists. Curr Opin Rheumatol 2017;29:458-66. [PMID: 28538012 DOI: 10.1097/BOR.0000000000000410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Balbi GGM, Pacheco MS, Monticielo OA, Funke A, Danowski A, Santiago MB, Staub HL, Rêgo J, de Andrade DCO. Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). Adv Rheumatol 2020;60:29. [PMID: 32460902 DOI: 10.1186/s42358-020-00125-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev 2020;10:CD012169. [PMID: 33045766 DOI: 10.1002/14651858.CD012169.pub3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Cohen H, Efthymiou M, Isenberg DA. Use of direct oral anticoagulants in antiphospholipid syndrome. J Thromb Haemost 2018;16:1028-39. [PMID: 29624847 DOI: 10.1111/jth.14017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
22 Arachchillage DRJ, Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol 2017;178:181-95. [PMID: 28339096 DOI: 10.1111/bjh.14632] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 10.6] [Reference Citation Analysis]
23 Keragala CB, Draxler DF, McQuilten ZK, Medcalf RL. Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways. Br J Haematol 2018;180:782-98. [PMID: 29265338 DOI: 10.1111/bjh.15062] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
24 Dobrowolski C, Erkan D. Treatment of antiphospholipid syndrome beyond anticoagulation. Clin Immunol 2019;206:53-62. [PMID: 29510235 DOI: 10.1016/j.clim.2018.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
25 Stachowicz A, Zabczyk M, Natorska J, Suski M, Olszanecki R, Korbut R, Wiśniewski JR, Undas A. Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism. Sci Rep 2018;8:17301. [PMID: 30470809 DOI: 10.1038/s41598-018-35034-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
26 Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev 2017;10:CD012169. [PMID: 28968483 DOI: 10.1002/14651858.CD012169.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
27 Raharja A, Chng CC, Timmis A. A swollen leg and cerebral infarctions in a 49-year-old woman. Br J Hosp Med (Lond) 2018;79:714-5. [PMID: 30526107 DOI: 10.12968/hmed.2018.79.12.714] [Reference Citation Analysis]
28 Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Williams DJ, Willis R, Woller SC, Andrade D. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus 2020;29:1571-93. [PMID: 33100166 DOI: 10.1177/0961203320950461] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]